The Anthem Biosciences IPO is set to open on July 14, 2025, offering investors a chance to invest in one of India’s fastest-growing contract research, development, and manufacturing organizations (CRDMO). The company serves over 550 clients across 44 countries and has completed more than 8,000 projects. With revenues reaching ₹1,844.55 crore in FY 2025 and a strong focus on advanced modalities like ADCs and RNAi, the Anthem Biosciences IPO presents an opportunity to participate in the expanding pharmaceutical outsourcing sector. Scheduled for subscription from July 14 to July 16, 2025, the IPO aims to raise ₹3,395 crore entirely through an offer for sale by existing shareholders.
₹175
₹570
₹723.05
Expert Opinions
The Anthem Biosciences IPO is generating strong market interest, reflecting the company’s rapid growth and leadership in the CRDMO space. Anthem’s strengths include a diversified global client base, advanced technology platforms, and expertise in both chemical and biological drug development, serving over 550 clients in 44+ countries. For FY 2025, the Anthem Biosciences IPO shows robust financials with a Return on Equity (ROE) of 20.82%, ROCE of 26.88%, and Net Asset Value (NAV) of ₹43.10, underscoring efficient capital use and profitability.
However, risks include reliance on global pharma spending cycles, regulatory complexities, and the absence of fresh issue proceeds for future expansion. From a long-term perspective, Anthem’s innovation-driven model, strong margins, and global reach position it as an attractive investment for those seeking exposure to high-growth life sciences, though investors should remain mindful of sector volatility and execution risks.
Investor Considerations
Investors evaluating the Anthem Biosciences IPO should note the company’s strong fundamentals, with FY 2025 revenue rising 30% to ₹1,930 crore and net profit up 23% to ₹451 crore, reflecting robust operational execution and global client traction. The sector outlook is positive, as demand for contract research and manufacturing services grows globally, driven by pharmaceutical innovation and outsourcing trends.
For FY 2025, the Anthem Biosciences IPO is valued at a Price to Book Value of 13.23, boasts a healthy PAT margin of 23.38%, and maintains a very low Debt/Equity ratio of 0.05, underscoring strong profitability and prudent leverage. Growth prospects are supported by ongoing facility expansion and a diversified client base across 44 countries. Key risks include high client concentration, regulatory complexity, and the lack of fresh capital for expansion. While short-term listing gains are possible, the IPO is best suited for long-term investors seeking exposure to a high-growth, innovation-led life sciences company.
| Date | GMP | Trend |
|---|---|---|
| 20 Jul 2025 13.05 | ₹175 | Up |
| 19 Jul 2025 19.30 | ₹155 | Up |
| 18 Jul 2025 19.22 | ₹130 | Down |
| 17 Jul 2025 12.51 | ₹150 | Down |
| 16 Jul 2025 10.42 | ₹160 | Up |
| 15 Jul 2025 19.52 | ₹140 | Up |
| 14 Jul 2025 16.00 | ₹110 | Up |
| 13 Jul 2025 15.27 | ₹100 | Up |
| 12 Jul 2025 16.01 | ₹90 | Down |
| 11 Jul 2025 10.14 | ₹110 | --- |
| 10 Jul 2025 19.26 | ₹110 | Up |
| 09 Jul 2025 19.28 | ₹95 | Up |
| 08 Jul 2025 17.10 | ₹75 | --- |
FAQs
The Grey Market Premium showed good accuracy in predicting Anthem Biosciences IPO’s listing performance. With a final GMP of ₹175, it suggested a premium of 30.70% over the issue price of ₹570. The stock listed at ₹723.05, delivering a slightly higher gain of 26.89%. This resulted in a small prediction error of 3.81%, where the GMP accurately signaled a strong positive listing and closely reflected the actual gain, demonstrating good reliability in this case.
Anthem Biosciences IPO Current GMP is ₹175.
Anthem Biosciences IPO Expected Returns is 30.70%.
Anthem Biosciences IPO estimated listing price is ₹745.